Live Analyst Rating Changes 1515 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Mark Marcon
BAIRD
Mark Marcon
Robert W. Baird
Wall Street Analyst
★★★★☆
#602
on 13Foresight · ranked by our own returns
61%
Success Rate
-0.4%
Average Return
11 of 18 calls profitable · -13.4% vs benchmark
📈 Across the calls we could measure, roughly 61% of Mark Marcon's ratings turned a profit when each position was held for 2 year — averaging -0.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

14 Buy 7 Hold 0 Sell
Mark's Stock Coverage 18 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
ANDG
Andersen Group, Inc. Class A
 May 13, 2026 BUY Strong Buy
+6.3% avg upside
7 analysts
$44.00
18.38% Upside
 +7.4%
AMN
AMN Healthcare Services
 May 11, 2026 HOLD Buy
+35.2% avg upside
14 analysts
$26.00
16.06% Downside
 -5.5%
PCTY
Paylocity
 May 08, 2026 BUY Strong Buy
+63.8% avg upside
30 analysts
$193.00
90.90% Upside
 -3.5%
WTW
Willis Towers Watson
 May 01, 2026 BUY Strong Buy
+28.4% avg upside
28 analysts
$335.00
31.30% Upside
 +2.5%
ADP
Automatic Data Processing
 Apr 30, 2026 HOLD Hold
+5.1% avg upside
27 analysts
$270.00
23.72% Upside
 +3.4%
KFRC
Kforce
 Apr 28, 2026 BUY Buy
+9.6% avg upside
9 analysts
$42.00
7.45% Downside
 +2.4%
EFOR
Everforth
 Apr 23, 2026 HOLD Buy
+131.2% avg upside
13 analysts
$38.00
99.19% Upside
 ·
MAN
ManpowerGroup
 Apr 17, 2026 BUY Buy
+69.7% avg upside
16 analysts
$45.00
34.10% Upside
 +10.5%
PAYX
Paychex
 Mar 26, 2026 HOLD Hold
+4.9% avg upside
26 analysts
$125.00
27.32% Upside
 +6.3%
WDAY
Workday
 Feb 24, 2026 BUY Strong Buy
+70.9% avg upside
53 analysts
$190.00
62.52% Upside
 -8.1%
TBI
Trueblue
 Feb 19, 2026 BUY Strong Buy
+166.2% avg upside
5 analysts
$5.50
17.85% Downside
 +42.2%
PAYC
Paycom
 Feb 12, 2026 BUY Buy
+65.2% avg upside
32 analysts
$183.00
46.59% Upside
 +3.9%
NSP
Insperity
 Feb 11, 2026 HOLD Buy
+36.0% avg upside
6 analysts
$36.00
0.52% Downside
 +21.1%
RHI
Robert Half
 Jan 30, 2026 BUY Buy
+32.6% avg upside
14 analysts
$50.00
58.28% Upside
 -25.6%
KFY
Korn Ferry
 Jun 13, 2024 BUY Strong Buy
+10.2% avg upside
9 analysts
$79.00
10.52% Upside
 -4.4%
HQY
Healthequity
 Jun 03, 2024 BUY Strong Buy
+33.4% avg upside
20 analysts
$104.00
22.15% Upside
 +4.9%
RGP
Resources Connection
 Apr 03, 2024 HOLD Buy
+301.4% avg upside
11 analysts
$13.00
207.30% Upside
 -66.2%
NFLX
Netflix
 Feb 28, 2014 HOLD Strong Buy
+126.0% avg upside
78 analysts
 — +48.8%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Mark Marcon — Frequently Asked Questions
How accurate are Mark Marcon's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Mark's ratings were profitable over a one-year hold, with an average return of +4.0% per rating, or -3.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Mark ranked on 13Foresight?
Mark Marcon is currently ranked #602 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Mark cover?
Mark most recently has ratings on ANDG, AMN, PCTY, WTW, ADP, KFRC, EFOR, MAN, PAYX, WDAY, TBI, PAYC and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.